09:00 - 10:00 Opening Ceremony

• P Rojnuckarin & S Hongeng (TSH)
• A Almeida & G Gaidano (EHA)

10:00 - 11:45  Session 1: Lymphoid malignancies

Chairs: R Kar (India) & MHFA Rahman (Malaysia)

• Updates of diffuse large B cell lymphoma and follicular lymphoma
  G Gaidano (Italy)
• CLL genes and microenvironment
  D Efremov (Italy)
• COVID and SARS-CoV2 vaccination in lymphoma patients
  S Haggenburg (Netherlands)
• Panel Discussion
  All speakers

11:45 - 13:15 Lunch

12:00 - 13:00 Lunch Symposium 1: Roche Thailand

• Advancements in the treatment of diffuse large B-cell lymphoma
  M Trneny (Czech Republic)

13:15 - 15:00 Session 2: Acute Leukemia

Chairs: P Niparuck (Thailand) & N Ali (Pakistan)

• VIRTUAL Molecular landscape in elderly AML
  L Bullinger (Germany)
• Impact of measurable residual disease for precision medicine in AML
  S Freeman (United Kingdom)
• Cellular Therapy in Pediatric Leukemias
  U Anurathapan (Thailand)
• Panel Discussion
  All speakers

15:00 - 15:15 Coffee break

15:15 - 17:00 Session 3: Red cell disorders & Bone marrow failure

Chairs: A Aziz (Bangladesh) & A Mirasol (Philippines)

• Guidelines on Use of NGS in the diagnosis of congenital anemias
  N Roy (United Kingdom)
• Fanconi anemia as a paradigm of clonal evolution in a deficient hematopoiesis
  J Soulier (France)
• VIRTUAL Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management
  A Taher (Lebanon)
• Panel Discussion
  All speakers

09:00 - 11:00 Regional Joint Symposium: Thalassemia registry and regional perspectives

Chairs: A Almeida (Portugal) & S Hongeng (Thailand)

• Thalassemia registry in Thailand: from evidence to real-world practices
  N Teawtrakul (Thailand)
• Thalassaemia in Bangladesh: Current Perspective
  M Rahman (Bangladesh)
  
• Spectrum of Thalassemias and Hemoglobinopathies in Southern India
  R Kar (India)
• Thalassemia Registry and regional perspectives: Malaysian Triumphs and Tribulations
  V Selvaratnam (Malaysia)
• Stem cell transplant in thalassemia - where do we stand?
  N Ali (Pakistan)
• The Newborn Screening Program For Hemoglobin Disorders: The 8 Year Philippine Experience
  R De Castro (Philippines)
• Thalassemia in Sri Lanka; Thalassemia registry and preventive strategies
  A Amaresena (Sri Lanka)
  
• Panel Discussion
  All Speakers

11:00 - 11:15 Coffee break

11:15 - 12:30 Session 4: Multiple Myeloma

Chairs: AH Masud (Bangladesh) & GG Gan (Malaysia)

• Can novel triplets replace ASCT in Newly Diagnosed Multiple Myeloma (NDMM)?
  R Mina (Italy)
• Which BCMA therapy has the future: CAR-T or bispecifics?
  N van de Donk (The Netherlands)
• Panel Discussion
  All Speakers

12:30 - 14:00 Lunch
12:45 - 13:45 Lunch Symposium 2: AstraZeneca

• Recent update of management of chronic lymphocytic leukemia (CLL) in the era of BTK inhibitors
  L Norasetthada (Thailand)

14:00 - 15:45 Session 5: MDS/MPN

Chairs: HP Pati (India) & J Relos (Philippines)

• New targets: Can we achieve disease modification in MF?
  J Kiladjian (France)
• From clonal hematopoiesis to myeloid malignancy – options for leukemia prevention?
  K Grønbæk (Denmark)
• Immune system in MDS
  A Almeida (Portugal)
• Panel Discussion
  All Speakers

15:45 - 16:00 Coffee break

16:00 - 17:15 Session 6: Thrombosis

Chairs: M Abiera (Philippines) & P Rojnuckarin (Thailand)

• Overview - EHA Guidelines on Management of anti-thrombotic treatment in thrombocytopenic patients with cancer
  H Ten Cate (The Netherlands)
• Hormone-associated venous thromboembolism: How mechanistic insights and lessons from clinical studies shape the patient journey
  P Sandset (Norway)
• Panel Discussion
  All Speakers

17:15 - 17:45 Closing ceremony